First NOAC reversal agent Praxbind lands in multiple univ. hospitals
The Boehringer Ingelheim’s first reversal agent for novel oral anticoagulants(NOAC), ‘Praxbind(idarucizumab),’ is promptly landing in large university hospitals after its launch.
After the launch last June, Praxbind first became available for prescription as passing the 134th Drug Committee of A...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
